## Abstract The aim of this study was to develop a standardized effective thrombogenic arterial anastomosis model, as usually encountered in clinical practice, and to offer a detailed evaluation of the antithrombotic effect of thrombin's direct inhibitors, antithrombin III and hirudin, as locally a
Microvascular repair following a modified crush-avulsion injury in a rat model: Effect of recombinant human tissue-type plasminogen activator on the patency rate
✍ Scribed by Efstathios G. Lykoudis; Petros N. Panayotou; Constantinos N. Stamatopoulos; Konstantina B. Frangia; Apostolos E. Papalois; John D. Ioannovich
- Publisher
- John Wiley and Sons
- Year
- 2000
- Tongue
- English
- Weight
- 579 KB
- Volume
- 20
- Category
- Article
- ISSN
- 0738-1085
No coin nor oath required. For personal study only.
✦ Synopsis
The failure rate of replantations following a crush-avulsion type injury is high. This study has been designed to reproduce an effective standardized crush-avulsion injury model to the femoral artery of the rat and evaluate the antithrombotic efficacy of systemic intravenous administration of recombinant human tissue-type plasminogen activator (rt-PA). The crush-avulsion injury was reproduced by using a bulldog clamp and two hemostats and followed by microvascular repair. The animals were divided into three groups of 20 rats each and received either normal saline, heparin 100 U/kg body weight, or rt-PA 3.5 mg/kg body weight intravenously. Patency tests were performed 20 min and 48 h after blood flow reestablishment. Results showed that this experimental crush-avulsion injury model ensures low patency in the control group, whereas systemic rt-PA administration improves the patency rate statistically significantly compared to control and heparin groups at both 20 min and 48 h postrevascularization.
📜 SIMILAR VOLUMES
## Abstract Vein thrombosis is often encountered in microsurgery, especially in the case of crush‐avulsion injuries. The aim of this study was to investigate the effect of systemic administration of recombinant tissue‐type plasminogen activator (rt‐PA) on the patency of the femoral vein of the rat,